Rani Therapeutics Holdings, Inc (RANI) Prices 6.7M Share IPO at $11/sh
- Wall St tumbles on weak consumer sentiment, rising bond yields
- Ford (F) Stock Soars on $11.4 Billion EV Partnership with Battery Maker SK Innovation (SKOVF)
- Brent oil dips after topping $80 a barrel, highest since Oct, 2018
- Piper Sandler Raises Estimates on Tesla (TSLA) Ahead of 'Best-Ever Quarter' in Q3
- Buy-the-dip Mentality Continues to Dominate, Last Week's $5.9 Billion Stock Inflows Were Fourth Largest Since 2008 - BofA
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of $11.00 per share. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $73.3 million. In addition, Rani has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol “RANI” on July 30, 2021. The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.
BofA Securities, Stifel, Cantor Fitzgerald and Canaccord Genuity are acting as lead bookrunning managers and BTIG is acting as co-manager for the offering.
The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained from: BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at email@example.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720, or by email at firstname.lastname@example.org; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at email@example.com; and Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, Boston MA 02110, or by email at firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on July 29, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fluence Files IPO
- Direct Selling Acquisition (DSAQU) Prices 20M Unit IPO at $10/unit
- Berenson Acquisition Corp. I (BACA) IPO Prices at $10
Create E-mail Alert Related CategoriesCorporate News, IPOs
Related EntitiesStifel, Cantor Fitzgerald, Canaccord Genuity, IPO, BTIG
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!